Brokerage firm Goldman Sachs Downgrades its rating on Atara Biotherapeutics Inc(NASDAQ:ATRA). In a research note issued to the investors, the brokerage major Lowers the price-target to $16.00 per share. The shares have been rated Sell. Previously, the analysts had a Neutral rating on the shares. The rating by Goldman Sachs was issued on Sep 15, 2016.
In a different note, On Aug 22, 2016, Citigroup said it Maintains its rating on Atara Biotherapeutics Inc. In the research note, the firm Lowers the price-target to $10.00 per share. The shares have been rated ‘Sell’ by the firm. On Aug 19, 2016, Citigroup said it Maintains its rating on Atara Biotherapeutics Inc. In the research note, the firm Lowers the price-target to $10.00 per share. The shares have been rated ‘Sell’ by the firm.
Atara Biotherapeutics Inc (ATRA) made into the market gainers list on Tuesdays trading session with the shares advancing 5.53% or 1.06 points. Due to strong positive momentum, the stock ended at $20.23, which is also near the day’s high of $20.58. The stock began the session at $19.44 and the volume stood at 2,18,960 shares. The 52-week high of the shares is $49.37 and the 52 week low is $13.31. The company has a current market capitalization of $583 M and it has 2,88,11,019 shares in outstanding.
Atara Biotherapeutics Inc(ATRA) last announced its earnings results on Aug 8, 2016 for Fiscal Year 2016 and Q2.Earnings per share were $-0.66. Analysts had estimated an EPS of $-0.61.
Several Insider Transactions has been reported to the SEC. On Aug 23, 2016, Isaac E. Ciechanover (Chief Executive Officer) sold 9,600 shares at $22.33 per share price.Also, On Aug 17, 2016, Christopher Haqq (Chief Medical Officer) sold 1,346 shares at $22.14 per share price.On Aug 17, 2016, Gad Soffer (Chief Operating Officer) sold 5,356 shares at $21.69 per share price, according to the Form-4 filing with the securities and exchange commission.
Atara Biotherapeutics Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing therapeutics for serious unmet medical needs with an initial focus on muscle wasting conditions and oncology. The Company’s lead product candidate PINTA 745 is a peptibody that binds myostatin and inhibits its corresponding signal transduction thereby blocking the negative regulation of skeletal muscle growth. PINTA 745 is in a Phase II clinical trial. The Company’s second product candidate STM 434 which is in a Phase I clinical study is a soluble ActR2B receptor that binds Activin A. The Company has five additional product candidates: ATA 842 a humanized antibody targeting myostatin; ATA 777 a fully human antibody targeting Activin A; ATA M43 a fully human anti-ActR2A/2B monoclonal antibody; STM 217 a soluble ActR2B receptor-IgG Fc fusion protein and a close analog of STM 434 and ActR2B5 a soluble ActR2B receptor that can be fused to an IgG Fc receptor.